I like:
- Increase of 121% on the March quarter 2019.
- Financial year-end Cash Receipts to June 2019 of $32,221,000 wereup 36% compared to the prior financial year (to June 2018).- This indicates that more EPP patients in Europe arereceiving treatment with SCENESSE® and we look forward to the time the same treatment access can be provided toAmerican EPP patients who have no current alternatives.”
- Net Cash from Operations was positive by $8,618,000 in the June quarter 2019. Net Cash from Operations for thetwelve months to 30 June 2019 was a positive $18,382,000 compared to a positive $11,693,000 in the same twelvemonth period to 30 June 2018.
- Increasing cash balance - Cash Balance as at 30 June2019 increased to $54,269,000, compared to $44,975,000 as at 31 March 2019 and $36,198,000 as at 30 June 2018.
Very positive outlook and building blocks foundation.
Well done!
- Forums
- ASX - By Stock
- Ann: Appendix 4C - quarterly
I like:- Increase of 121% on the March quarter 2019.- Financial...
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.50 |
Change
-0.070(0.45%) |
Mkt cap ! $776.6M |
Open | High | Low | Value | Volume |
$15.60 | $15.66 | $15.50 | $142.9K | 9.168K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 118 | $15.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.55 | 201 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 45 | 15.500 |
2 | 134 | 15.490 |
3 | 1118 | 15.480 |
4 | 397 | 15.470 |
2 | 402 | 15.460 |
Price($) | Vol. | No. |
---|---|---|
15.540 | 174 | 6 |
15.550 | 314 | 4 |
15.560 | 2242 | 6 |
15.570 | 83 | 1 |
15.580 | 1183 | 3 |
Last trade - 10.54am 27/05/2024 (20 minute delay) ? |
|
|||||
Last
$15.52 |
  |
Change
-0.070 ( 0.44 %) |
|||
Open | High | Low | Volume | ||
$15.63 | $15.63 | $15.50 | 397 | ||
Last updated 11.06am 27/05/2024 ? |
Featured News
CUV (ASX) Chart |